In one paragraphArticle in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Thomas S CorriganDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-5113-9406 Sarah E BorderDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-5739-3093 Leilani M Lotti DiazDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-5955-9595 Kayla Q KasperDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0009-0004-7651-892X Abigail M NoonchesterDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0009-0007-2302-635X Kayla S KucwayDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0009-0004-1078-1389 Michael FleisherDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0009-0009-1015-1551 Joseph P FernandezDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-3744-3206 Alex R LovinsDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0009-0002-5850-1708 Ana K SerranoSkaggs School of Pharmacy and Pharmaceutical Sciences, Center for Discovery and Innovation in Parasitic Diseases, University of California San Diego, La Jolla, CA, USA.ORCID 0009-0006-8928-4135 Conor R CaffreySkaggs School of Pharmacy and Pharmaceutical Sciences, Center for Discovery and Innovation in Parasitic Diseases, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-3048-8572 Anthony J O'DonoghueSkaggs School of Pharmacy and Pharmaceutical Sciences, Center for Discovery and Innovation in Parasitic Diseases, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-5695-0409 Don M BensonDepartment of Internal Medicine, Division of Hematology, The Ohio State University Medical Center, Columbus, OH, USA.ORCID 0000-0001-8837-0548 Christopher M HadadDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-1211-4315 Özlem Doğan EkiciDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-1237-1269 Funding
Proteasome inhibitors against mucosal protozoan pathogensR01AI158612 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2021 to 2025
$3.2MThe catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435kNIAID NIH HHS R01 AI158612NIAID NIH HHS R21 AI171824
6 · The paper itselfAbstract
aimsAza-peptide aldehydes and ketones were developed as a new class of peptidyl analogues to inhibit the human constitutive (c)20S proteasome as alternative therapeutics to treat multiple myeloma (MM). MATERIAL AND
methodsEleven new aza-peptide aldehydes and ketones were designed based on their preference to bind at the ß5 catalytic subunit of c20S proteasome with benzyloxycarbonyl(Cbz)-Leu-Leu-Leu (MG132-like) and morpholinyl(Mp)-Homophenylalanyl(HPh)-Leu-Phe-Leu (Carfilzomib-like) sequences, synthesized, structurally characterized and evaluated for their inhibitory potency in competitive kinetic assays in vitro. Additionally, cell viability assays and molecular modeling experiments were designed and performed in support.
resultsAza-peptide aldehydes and ketones generated inhibitory activity with IC
conclusionsOverall, aza-peptide aldehydes and ketones are a new class of selective human c20S proteasome inhibitors with the potential for further development as alternative therapeutics for multiple myeloma.
Indexed as
Antineoplastic AgentsProteasome InhibitorsAldehydesAza CompoundsCell LineCell SurvivalDrug Screening Assays, AntitumorKetonesMolecular StructureMultiple MyelomaPeptidesAldehydesAntineoplastic AgentsAza CompoundsKetonesPeptidesProteasome Inhibitorsanticanceraza-peptide aldehydesaza-peptide ketonesmultiple myelomaProteasome inhibitor
Identifiers
PMID41099163
PMCPMC12536793
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390